January 29, 2019 — MaxQ AI and GE Healthcare announced that MaxQ's Accipio artificial intelligence (AI) platform will now be a part of GE Healthcare's Computed Tomography (CT) Smart Subscription offering. GE Healthcare's Smart Subscription provides customers with continuous access to the latest imaging software updates, through an available automatic download to their CT scanners from the cloud. As a Smart Subscription offering, hospitals with GE Healthcare CTs can easily and seamlessly integrate MaxQ's Accipio platform, from which Accipio Ix intracranial hemorrhage (ICH) detection software is now available.
GE Healthcare's Smart Subscription is a service that supports the integration and seamless deployment of new innovations such as AI-enabled offerings to keep CT scanners current, reduce variability and bring intelligent imaging into hospitals. Smart Subscription offers flexible options for smarter budgeting, giving health systems, hospitals and clinics the opportunity to standardize applications across all CT units, and select the applications they need, with an option to add or remove applications at any time.
Accipio Ix, which has received both U.S. Food and Drug Administration (FDA) clearance and CE Mark certification, leverages artificial intelligence technology to automatically analyze non-contrast head CT images. The AI-powered Accipio Ix, part of MaxQ's Accipio Insight platform, is designed to be highly sensitive to the presence of ICH, identifying and prioritizing patients with a brain bleed for the treating physician. It provides a capability for rapid escalation and prioritization of the patient and can be natively integrated into CT and picture archiving and communication systems (PACS) using DICOM, installed both on-premise and in the future, cloud-capable.
MaxQ demonstrated Accipio Ix, along with the full suite of Accipio platform solutions, during the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago.
For more information: www.maxq.ai, www.gehealthcare.com
April 29, 2024 
